AIM ImmunoTech announced NCI award of $14.54 million to study Ampligen as part of five Roswell Park-led chemokine modulation clinical trials in melanoma, colorectal and ovarian cancers

AIM ImmunoTech announced NCI award of $14.54 million to study Ampligen as part of five Roswell Park-led chemokine modulation clinical trials in melanoma, colorectal and ovarian cancers

On Apr. 6, 2020, the National Cancer Institute awarded of $14.54 million to Roswell Park Comprehensive Cancer Center…